Susan Greenfield speaking at OBN’s BioTuesday

Susan Greenfield speaking at OBN’s BioTuesday

Susan would like to mention her following thoughts with regards to the OBN presentation: “Our technology is based on the previously unknown neurochemical (T14), that is doubled in the Alzheimer brain. We are developing a pre-symptomatic screen where T14 could be...
Johnny Thompson joins Neuro-Bio

Johnny Thompson joins Neuro-Bio

Neuro-Bio is delighted to welcome Johnny Thompson as a Consultant. Johnny is a recent neuroscience graduate from the University of Exeter who has a keen interest in Alzheimer’s disease. Johnny has previously worked as a business analyst intern for Ferghana Partners...